+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-06-27Number of Pages: 251

Diabetic Neuropathy Market (Disorder Type - Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy; Treatment Type - Drugs (Analgesic (Topical, Opioid, and NSAIDs), Antidepressants (TCAs, SNRIs, and SSRIs), and Anticonvulsant Drugs (Gabapentin, Pregabalin, and Topiramate), Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS)), and Physiotherapy; Distribution Channel - Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Diabetic Neuropathy Market: Snapshot

A handful of international and local manufacturers with limited shares dominate the global diabetic neuropathy market. This makes the competitive landscape semi-consolidated in nature. The competition among them is intense with most spending time and money on research and development of more effective neuropathy drugs.

The global diabetic neuropathy market is being primarily driven by changing lifestyles which has mostly resulted in unhealthy dietary habits and patterns. As per WHO, about 422 were afflicted by diabetes in 2014. Apart from that, other growth drivers in the market are the approval of novel drugs to treat neuropathic pain and supportive reimbursement policies.

Drugs administered to treat neuropathic pain, however, so far have had only limited success in terms of pain relief. This coupled with erroneous diagnosis or selection of treatment and side effects and rising cost of diabetic neuropathy treatment drugs are posing a hindrance to the market for diabetic neuropathy market.

A report by Transparency Market Research, forecasts the global diabetic neuropathy market to become worth US$5.718 bn by 2024 from US$ 3.6 bn in 2016 by rising at a steady CAGR of 5.4% between 2017 and 2025.

diabetic neuropathy market

 

Peripheral Neuropathy to Retain its Dominant Share by Clocking Maximum Growth

Peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy are the prominent disorders in the global diabetic neuropathy market. Peripheral neuropathy, of them, accounts for almost half the share in the market at present. In the near future it is predicted to grow its share marginally by surpassing all other segments in terms of growth rate. The report by TMR predicts the segment to clock a 5.7% CAGR from 2017 to 2025 because of the high prevalence of diabetic neuropathy.

Proximal neuropathy follows peripheral neuropathy when it comes to market share in the global diabetic neuropathy market. This is because proximal diabetic neuropathy is the most commonly found disorder in type 2 diabetes. The segment was worth US$885.6 mn in 2016 and will likely rise to US$1.405 mn by 2025 by expanding at a CAGR of 5.4% from 2017 to 2025.

Major Players Target North America Market Having Large Patient Pool

Key regional segments in the global diabetic neuropathy market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among them, North America accounted for a market leading share of 34.9% in 2016. This is mainly on account of the large pool of patients who have been diagnosed and the expensiveness of therapy. In fact, keen companies are eyeing the market in U.S. in the region to up sales and revenues. The market in North America was worth US$1.071 bn in 2016 and rising at 5.3% CAGR between 2017 and 2025, it is slated to become worth US$1.68 bn by 2025.

Europe trails North America in the global diabetic neuropathy market in terms of size. Its market has been mostly driven by the rising occurrence of diabetic neuropathy and a growing pool of elderly, particularly in countries of Italy, Germany, France, and the U.K. In terms of growth rate, however, the market is Asia Pacific is predicted to outshine all others. Powered primarily by China, Asia Pacific will likely clock a CAGR of 6.7% on account of the growing number of healthcare awareness programs, hospitals equipped with radiology devices to treat diabetic neuropathy, and a large pool of patients.

Some of the key names operating in the market are Pfizer, Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd, and Arbor Pharmaceuticals, LLC.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Diabetic Neuropathy Market 

4. Market Overview
     4.1. Introduction
             4.1.1 Product Definition
             4.1.2 Industry Evolution / Developments
     4.2 Overview
     4.3 Key Market Indicators
             4.3.1 Region/Country Specific
             4.3.2 Product/Application/Disease Indication Specific
             4.3.3 Target Market Specific – Global Scenario
     4.4 Market Dynamics
             4.4.1 Drivers
             4.4.2 Restraints
             4.4.3 Opportunity
     4.5 Global Diabetic Neuropathy Market  Analysis and Forecasts, 2015–2025
             4.5.1 Market Revenue Projections (US$ Mn)
     4.6 Diabetic Neuropathy Market  - Global Supply Demand Scenario
     4.7 Porter’s Five Force Analysis
     4.8 Market Outlook
     4.9 Diabetic Neuropathy Market : Pipeline Analysis
     4.10 Diabetic Neuropathy : Prevalence Data & Percentage of Patient Receiving Treatment

5. Global Diabetic Neuropathy Analysis and Forecasts, By Disorder Type 
     5.1 Introduction & Definition     
     5.2 Key Findings / Developments
     5.3 Key Trends
     5.4 Market Value Forecast By Disorder Type , 2015–2025
             5.4.1 Peripheral Neuropathy
             5.4.2 Autonomic Neuropathy
             5.4.3 Proximal Neuropathy
             5.4.4 Focal Neuropathy 
     5.5 Market Attractiveness By Disorder Type 

6. Global Diabetic Neuropathy Analysis and Forecasts, By Treatment Type 
     6.1 Introduction & Definition     
     6.2 Key Findings / Developments
     6.3 Key Trends
     6.4 Market Value Forecast By Treatment Type, 2015–2025
             6.4.1 Drug
                      6.4.1.1 Analgesic
                                 6.4.1.1.1 Topical
                                              6.4.1.1.1.1  Capsaicin
                                              6.4.1.1.1.2  Others
                                 6.4.1.1.2 Opioids
                                              6.4.1.1.2.1 Morphine
                                              6.4.1.1.2.2 Others
                                 6.4.1.1.3 NSAIDs
                                              6.4.1.1.3.1 Ibuprofen
                                              6.4.1.1.3.2 Naproxen
                                              6.4.1.1.3.3 Others
                      6.4.1.2 Antidepressant
                                 6.4.1.2.1 TCAs
                                              6.4.1.2.1.1 Amitriptyline
                                              6.4.1.2.1.2 Imipramine
                                              6.4.1.2.1.3 Others
                                 6.4.1.2.2 SNRIs
                                              6.4.1.2.2.1 Duloxetine
                                              6.4.1.2.2.2 Others
                                 6.4.1.2.3 SSRIs
                                              6.4.1.2.3.1 Citalopram
                                              6.4.1.2.3.2 Paroxetin
                                              6.4.1.2.3.3 Others
                      6.4.1.3. Anticonvulsants
                                 6.4.1.3.1 Gabapentin
                                 6.4.1.3.2 Pregabalin
                                 6.4.1.3.3 Topimarate
                                 6.4.1.3.4 Others
                      6.4.1.4. Other Drugs
             6.4.2 Radiotherapy
                      6.4.2.1 TENS
                      6.4.2.2 Other
             6.4.3 Physiotherapy
     6.5 Market Attractiveness By Treatment 

7. Global Diabetic Neuropathy Market  Analysis and Forecasts, By Distribution Channel
     7.1 Introduction & Definition
     7.2 Key Findings / Developments
     7.3 Key Trends
     7.4 Market Value Forecast By Distribution Channel, 2015–2025
             7.4.1 Hospitals
             7.4.2 Clinics
             7.4.3 Retail Pharmacy 
             7.4.4 Online Pharmacy 
     7.5 Market Attractiveness By Distribution Channel

8. Global Diabetic Neuropathy Market  Analysis and Forecasts, By Region
     8.1 Key Findings
     8.2 Policies and Regulations
     8.3 Market Value Forecast By Region
             8.3.1 North America 
             8.3.2 Europe 
             8.3.3 Asia Pacific 
             8.3.4 Latin America 
             8.3.5 Middle East and Africa 
     8.4 Market Attractiveness By Country/Region

9. North America Diabetic Neuropathy Market  Analysis and Forecast
     9.1 Introduction
             9.1.1 Key Findings
             9.1.2 Policies and Regulations
             9.1.3 Key Trends
     9.2 Market Value Forecast By Disorder Type, 2015–2025
             9.2.1 Peripheral Neuropathy
             9.2.2 Autonomic Neuropathy
             9.2.3 Proximal Neuropathy
             9.2.4 Focal Neuropathy 
     9.3 Market Value Forecast By Treatment Type, 2015–2025
             9.3.1 Drug
                      9.3.1.1 Analgesic
                                 9.3.1.1.1 Topical
                                              9.3.1.1.1.1 Capsaicin
                                              9.3.1.1.1.2 Others
                                 9.3.1.1.2 Opioids
                                              9.3.1.1.2.1 Morphine
                                              9.3.1.1.2.2 Others
                                 9.3.1.1.3 NSAIDs
                                              9.3.1.1.3.1 Ibuprofen
                                              9.3.1.1.3.2 Naproxen
                                              9.3.1.1.3.3 Others
                      9.3.1.2. Antidepressant
                                 9.3.1.2.1 TCAs
                                              9.3.1.2.1.1 Amitriptyline
                                              9.3.1.2.1.2 Imipramine
                                              9.3.1.2.1.3 Others
                                 9.3.1.2.2 SNRIs
                                              9.3.1.2.2.1 Duloxetine
                                              9.3.1.2.2.2 Others
                                 9.3.1.2.3 SSRIs
                                              9.3.1.2.3.1 Citalopram
                                              9.3.1.2.3.2 Paroxetin
                                              9.3.1.2.3.3 Others
                      9.3.1.3. Anticonvulsants
                                 9.3.1.3.1 Gabapentin
                                 9.3.1.3.2 Pregabalin
                                 9.3.1.3.3 Topimarate
                                 9.3.1.3.4 Others
                      9.3.1.4. Other Drugs
             9.4.2. Radiotherapy
                      9.4.2.1. TENS
                      9.4.2.2. Other
             9.4.3. Physiotherapy
     9.4. Market Value Forecast By Distribution Channel, 2015–2025
             9.4.1. Hospitals
             9.4.2. Clinics
             9.4.3. Retail Pharmacy 
             9.4.4. Online Pharmacy 
     9.5. Market Value Forecast By Country , 2015–2025
             9.5.1. U.S.
             9.5.2. Canada
     9.6. Market Attractiveness Analysis 
             9.6.1. By Disorder Type
             9.6.2. By Treatment Type
             9.6.3. By Distribution Channel
             9.6.5. By Country

10. Europe Diabetic Neuropathy Market  Analysis and Forecast
     10.1. Introduction
             10.1.1. Key Findings
             10.1.2. Policies and Regulations
             10.1.3. Key Trends
     10.2. Market Value Forecast By Disorder Type, 2015-2025
             10.2.1. Peripheral Neuropathy
             10.2.2. Autonomic Neuropathy
             10.2.3. Proximal Neuropathy
             10.2.4. Focal Neuropathy 
     10.3. Market Value Forecast By Treatment Type, 2015–2025
             10.3.1. Drug
                      10.3.1.1. Analgesic
                                  10.3.1.1.1 Topical
                                              10.3.1.1.1.1 Capsaicin
                                              10.3.1.1.1.2 Others
                                 10.3.1.1.2 Opioids
                                              10.3.1.1.2.1 Morphine
                                              10.3.1.1.2.2 Others
                                 10.3.1.1.3 NSAIDs
                                              10.3.1.1.3.1 Ibuprofen
                                              10.3.1.1.3.2 Naproxen
                                              10.3.1.1.3.3 Others
                      10.3.1.2 Antidepressant
                                 10.3.1.2.1 TCAs
                                              10.3.1.2.1.1 Amitriptyline
                                              10.3.1.2.1.2 Imipramine
                                              10.3.1.2.1.3 Others
                                 10.3.1.2.2 SNRIs
                                              10.3.1.2.2.1 Duloxetine
                                              10.3.1.2.2.2 Others
                                 10.3.1.2.3 SSRIs
                                              10.3.1.2.3.1 Citalopram
                                              10.3.1.2.3.2 Paroxetin
                                              10.3.1.2.3.3 Others
                      10.3.1.3 Anticonvulsants
                                 10.3.1.3.1 Gabapentin
                                 10.3.1.3.2 Pregabalin
                                 10.3.1.3.3 opimarate
                                 10.3.1.3.4 Others
                      10.3.1.4 Other Drugs
             10.3.2 Radiotherapy
                      10.3.2.1 TENS
                      10.3.2.2 Other
             10.4.3 Physiotherapy
     10.4 Market Value Forecast By Distribution Channel, 2015–2025
             10.4.1 Hospitals
             10.4.2 Clinics
             10.4.3 Retail Pharmacy 
             10.4.4 Online Pharmacy 
     10.5 Market Value Forecast By Country, 2015–2025
             10.5.1 Germany
             10.5.2 France
             10.5.3 U.K.
             10.5.4 Spain
             10.5.5 Italy
             10.5.6 Russia
             10.5.7 Rest of Europe
     10.6 Market Attractiveness Analysis 
             10.6.1 By Disorder Type 
             10.6.2 By Treatment Type 
             10.6.3 By Distribution Channel
             10.6.4 By Country

11. Asia Pacific Diabetic Neuropathy Market  Analysis and Forecast
     11.1 Introduction
             11.1.1 Key Findings
             11.1.2 Policies and Regulations
             11.1.3 Key Trends
     11.2 Market Value Forecast By Disorder Type , 2015–2025
             11.2.1 Peripheral Neuropathy
             11.2.2 Autonomic Neuropathy
             11.2.3 Proximal Neuropathy
             11.2.4 Focal Neuropathy 
     11.3 Market Value Forecast By Treatment Type, 2015–2025
             11.3.1 Drug
                      11.3.1.1 Analgesic
                                 11.3.1.1.1 Topical
                                              11.3.1.1.1.1 Capsaicin
                                              11.3.1.1.1.2 Others
                                 11.3.1.1.2 Opioids
                                              11.3.1.1.2.1 Morphine
                                              11.3.1.1.2.2 Others
                                 11.3.1.1.3 NSAIDs
                                              11.3.1.1.3.1 Ibuprofen
                                              11.3.1.1.3.2 Naproxen
                                              11.3.1.1.3.3 Others
                      11.3.1.2 Antidepressant
                                 11.3.1.2.1 TCAs
                                              11.3.1.2.1.1 Amitriptyline
                                              11.3.1.2.1.2 Imipramine
                                              11.3.1.2.1.3 Others
                                 11.3.1.2.2 SNRIs
                                              11.3.1.2.2.1 Duloxetine
                                              11.3.1.2.2.2 Others
                                 11.3.1.2.3 SSRIs
                                              11.3.1.2.3.1 Citalopram
                                              11.3.1.2.3.2 Paroxetin
                                              11.3.1.2.3.3 Others
                      11.3.1.3 Anticonvulsants
                                 11.3.1.3.1 Gabapentin
                                 11.3.1.3.2 Pregabalin
                                 11.3.1.3.3 Topimarate
                                 11.3.1.3.4 Others
                      11.3.1.4 Other Drugs
             11.3.2 Radiotherapy
                      11.3.2.1 TENS
                      11.3.2.2 Other
             11.3.3 Physiotherapy
     11.4 Market Value Forecast By Distribution Channel , 2015–2025
             11.4.1 Hospitals
             11.4.2 Clinics
             11.4.3 Retail Pharmacy 
             11.4.4 Online Pharmacy 
     11.5 Market Value Forecast By Country , 2015–2025
             11.5.1 China
             11.5.2 Japan
             11.5.3 India
             11.5.4 Australia & New Zealand
             11.5.5 Rest of Asia Pacific
     11.6 Market Attractiveness Analysis 
             11.6.1 By Disorder Type
             11.6.2 By Treatment Type
             11.6.3 By Distribution Channel
             11.6.4 By Country
             
12. Latin America Diabetic Neuropathy Market  Analysis and Forecast
     12.1 Introduction
             12.1.1 Key Findings
             12.1.2 Policies and Regulations
             12.1.3 Key Trends
     12.2 Market Value Forecast By Disorder Type , 2015–2025
             12.2.1 Peripheral Neuropathy
             12.2.2 Autonomic Neuropathy
             12.2.3 Proximal Neuropathy
             12.2.4 Focal Neuropathy 
     12.3 Market Value Forecast By Treatment Type, 2015–2025
             12.3.1 Drug
                      12.3.1.1 Analgesic
                                 12.3.1.1.1 Topical
                                              12.3.1.1.1.1 Capsaicin
                                              12.3.1.1.1.2 Others
                                 12.3.1.1.2 Opioids
                                              12.3.1.1.2.1 Morphine
                                              12.3.1.1.2.2 Others
                                 12.3.1.1.3 NSAIDs
                                              12.3.1.1.3.1 Ibuprofen
                                              12.3.1.1.3.2 Naproxen
                                              12.3.1.1.3.3 Others
                      12.3.1.2 Antidepressant
                                 12.3.1.2.1 TCAs
                                              12.3.1.2.1.1 Amitriptyline
                                              12.3.1.2.1.2 Imipramine
                                              12.3.1.2.1.3 Others
                                 12.3.1.2.2 SNRIs
                                              12.3.1.2.2.1 Duloxetine
                                              12.3.1.2.2.2 Others
                                 12.3.1.2.3 SSRIs
                                              12.3.1.2.3.1 Citalopram
                                              12.3.1.2.3.2 Paroxetin
                                              12.3.1.2.3.3 Others
                      12.3.1.3 Anticonvulsants
                                 12.3.1.3.1 Gabapentin
                                 12.3.1.3.2 Pregabalin
                                 12.3.1.3.3 Topimarate
                                 12.3.1.3.4 Others
                      12.3.1.4 Other Drugs
             12.3.2 Radiotherapy
                      12.3.2.1 TENS
                      12.3.2.2 Other
             12.3.3 Physiotherapy
     12.4 Market Value Forecast By Distribution Channel , 2015–2025
             12.4.1 Hospitals
             12.4.2 Clinics
             12.4.3 Retail Pharmacy 
             12.4.4 Online Pharmacy 
     12.5 Market Value Forecast By Country , 2015–2025
             12.5.1 Brazil
             12.5.2 Mexico
             12.5.3 Rest of Latin America
     12.6 Market Attractiveness Analysis 
             12.6.1 By Disorder Type 
             12.6.2 By Treatment Type 
             12.6.3 By Distribution Channel 
             12.6.4 By Country

13. Middle East and Africa Diabetic Neuropathy Market  Analysis and Forecast
     13.1. Introduction
             13.1.1 Key Findings
             13.1.2 Policies and Regulations
             13.1.4 Key Trends
     13.2. Market Value Forecast By Disorder Type, 2015–2025
             13.2.1 Peripheral Neuropathy
             13.2.2 Autonomic Neuropathy
             13.2.3 Proximal Neuropathy
             13.2.4 Focal Neuropathy 
     13.3. Market Value Forecast By Treatment Type, 2015–2025
             13.3.1 Drug
                      13.3.1.1 Analgesic
                                 13.3.1.1.1 Topical
                                              13.3.1.1.1.1 Capsaicin
                                              13.3.1.1.1.2 Others
                                 13.3.1.1.2 Opioids
                                              13.3.1.1.2.1 Morphine
                                              13.3.1.1.2.2 Others
                                 13.3.1.1.3 NSAIDs
                                              13.3.1.1.3.1 Ibuprofen
                                              13.3.1.1.3.2 Naproxen
                                              13.3.1.1.3.3 Others
                      13.3.1.2 Antidepressant
                                 13.3.1.2.1 TCAs
                                              13.3.1.2.1.1 Amitriptyline
                                              13.3.1.2.1.2 Imipramine
                                              13.3.1.2.1.3 Others
                                 13.3.1.2.2 SNRIs
                                              13.3.1.2.2.1 Duloxetine
                                              13.3.1.2.2.2 Others
                                 13.3.1.2.3 SSRIs
                                              13.3.1.2.3.1 Citalopram
                                              13.3.1.2.3.2 Paroxetin
                                              13.3.1.2.3.3 Others
                      13.3.1.3 Anticonvulsants
                                 13.3.1.3.1 Gabapentin
                                 13.3.1.3.2 Pregabalin
                                 13.3.1.3.3 Topimarate
                                 13.3.1.3.4 Others
                      13.3.1.4 Other Drugs
             13.3.2 Radiotherapy
                      13.3.2.1 TENS
                      13.3.2.2 Other
             13.3.3 Physiotherapy
     13.4 Market Value Forecast By Distribution Channel , 2015–2025
             13.4.1 Hospitals
             13.4.2 Clinics
             13.4.3 Retail Pharmacy 
             13.4.4 Online Pharmacy 
     13.5 Market Value Forecast By Country , 2015–2025
             13.5.1 GCC Countries
             13.5.2 South Africa
             13.5.3 Rest of Middle East and Africa
     13.6 Market Attractiveness Analysis 
             13.6.1 By Disorder Type 
             13.6.2 By Treatment 
             13.6.3 By Distribution Channel 
             13.6.4 By Country

14. Competition Landscape
     14.1 Market Player – Competition Matrix (By Tier and Size of companies)
     14.2 Market Share Analysis By Company, 2016
     14.3 Company Profiles 
             14.3.1 Johnson & Johnson (Janssen Global Services, LLC)
                      14.3.1.1 Overview
                      14.3.1.2 Financials
                      14.3.1.3 Recent Developments
                      14.3.1.4 Strategy
             14.3.2. Boehringer Ingelheim GmbH
                      14.3.2.1 Overview
                      14.3.2.2 Financials
                      14.3.2.3 Recent Developments
                      14.3.2.4 Strategy
             14.3.3 NeuroMetrix, Inc.
                      14.3.3.1 Overview
                      14.3.3.2 Financials
                      14.3.3.3 Recent Developments
                      14.3.3.4 Strategy
             14.3.4 Eli Lilly and Company
                      14.3.4.1 Overview
                      14.3.4.2 Financials
                      14.3.4.3 Recent Developments
                      14.3.4.4 Strategy
             14.3.5 GlaxoSmithKline plc.
                      14.3.5.1 Overview
                      14.3.5.2 Financials
                      14.3.5.3 Recent Developments
                      14.3.5.4 Strategy
             14.3.6 Lupin Limited
                      14.3.6.1 Overview
                      14.3.6.2 Financials
                      14.3.6.3 Recent Developments
                      14.3.6.4 Strategy
             14.3.7 Pfizer Inc.
                      14.3.7.1 Overview
                      14.3.7.2 Financials
                      14.3.7.3 Recent Developments
                      14.3.7.4 Strategy
             14.3.8 Astellas Pharma Inc.,
                      14.3.8.1 Overview
                      14.3.8.2 Financials
                      14.3.8.3 Recent Developments
                      14.3.8.4 Strategy
             14.3.9 Glenmark Pharmaceuticals Ltd
                      14.3.9.1 Overview
                      14.3.9.2 Financials
                                 14.3.13.3 Recent Developments
                      14.3.9.4 Strategy
             14.3.10 Arbor Pharmaceuticals, LLC
                      14.3.10.1 Overview
                      14.3.10.2 Financials
                      14.3.13.3 Recent Developments
                      14.3.10.4 Strategy
             14.3.11 Depomed, Inc.
                      14.3.10.1 Overview
                      14.3.10.2 Financials
                      14.3.13.3 Recent Developments
                      14.3.10.4 Strategy

List of Figures

Figure 1: Global Diabetic Neuropathy, Market Size (US$ Mn) Forecast, 2015–2025
Figure 2: Global Diabetic Neuropathy Market Value Share, by Disorder Type, for 2017 and 2025
Figure 3: Global Diabetic Neuropathy Market Attractiveness Analysis, by Disorder Type, 2017–2025
Figure 4: Global Peripheral Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 5: Global Autonomic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 6: Global Proximal Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 7: Global Focal Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%) Projection, 2015–2025
Figure 8: Global Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 9: Global Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type, 2017–2025
Figure 10: Global Analgesic Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Antidepressant Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 12: Global Anticonvulsant Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 13: Global Other Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 15: Global Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 16: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
Figure 17: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2015–2025
Figure 18: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 19: Global Diabetic Neuropathy Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
Figure 20: Global Diabetic Neuropathy Market Value Share, by Region, 2017 and 2025
Figure 21: Global Diabetic Neuropathy Market Attractiveness Analysis, by Region, 2016–2024
Figure 22: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: North America Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 24: North America Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 25: North America Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 26: North America Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 27: North America Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 28: North America Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 29: North America Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 30: North America Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 31: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 32: Europe Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 33: Europe Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 34: Europe Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 35: Europe Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 36: Europe Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 37: Europe Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 38: Europe Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 39: Europe Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 40: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
Figure 41: Asia Pacific Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 42: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 43: Asia Pacific Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 44: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 45: Asia Pacific Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 46: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 47: Asia Pacific Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 48: Asia Pacific Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 49: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
Figure 50: Latin America Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 51: Latin America Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 52: Latin America Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 53: Latin America Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 54: Latin America Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 55: Latin America Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 56: Latin America Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 57: Latin America Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 58: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast and Y-o-Y Growth Projections (%), 2015–2025
Figure 59: Middle East & Africa Diabetic Neuropathy Market Value Share, by Country, 2017 and 2025
Figure 60: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Country, 2017–2025
Figure 61: Middle East & Africa Diabetic Neuropathy Market Value Share, by Disorder Type, 2017 and 2025
Figure 62: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Disorder Type, 2017–2025
Figure 63: Middle East & Africa Diabetic Neuropathy Market Value Share, by Treatment Type, 2017 and 2025
Figure 64: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Treatment Type, 2017–2025
Figure 65: Middle East & Africa Diabetic Neuropathy Market Value Share, by Distribution Channel, 2017 and 2025
Figure 66: Middle East & Africa Diabetic Neuropathy Market Attractiveness, by Distribution Channel, 2017–2025
Figure 67: Global Diabetic Neuropathy Market Share Analysis, by Company, 2016

List of Tables

Table 1: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 2: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 3: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 4: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 5: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 6: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 7: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 8: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 9: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 10: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 11: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 12: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 13: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 14: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 15: Global Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 16: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 17: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 18: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 19: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 20: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 21: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 22: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 23: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 24: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 25: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 26: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 27: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 28: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 29: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 30: North America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 31: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 32: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 33: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 34: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 35: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 36: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 37: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 38: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 39: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 40: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 41: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 42: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 43: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 44: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 45: Europe Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 46: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 47: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 48: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 49: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 50: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 51: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 52: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 53: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 54: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 55: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 56: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 57: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 58: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 59: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 60: Asia Pacific Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 61: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 62: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 63: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 64: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 65: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 66: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 67: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 68: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 69: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 70: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 71: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 72: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 73: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 74: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 75: Latin America Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 76: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 77: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Disorder Type, 2015–2025
Table 78: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 79: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 80: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Analgesic Drug Type, 2015–2025
Table 81: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Topical Drug Type, 2015–2025
Table 82: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Opioid Drug Type, 2015–2025
Table 83: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by NSAID Type, 2015–2025
Table 84: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Antidepressant Drug Type, 2015–2025
Table 85: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by TCA Drug Type, 2015–2025
Table 86: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SNRI Drug Type, 2015–2025
Table 87: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by SSRI Drug Type, 2015–2025
Table 88: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Anticonvulsant Drug Type, 2015–2025
Table 89: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Radiotherapy, 2015–2025
Table 90: Middle East & Africa Diabetic Neuropathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

Global Diabetic Neuropathy Market: Overview

The report on diabetic neuropathy market analyzes the current and future scenario of the global market. Increase in prevalence of diabetic neuropathy, advent of new therapeutics for treatment of neuropathy, favorable reimbursement scenario, and investment from key players in development of cost effective therapeutics for diabetic neuropathy are the major drivers of the global diabetic neuropathy market.

The diabetic neuropathy market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global diabetic neuropathy market with respect to the segments based on disorder type, treatment type, distribution channel and geography.

A detailed qualitative analysis of drivers and restraints of the market and its opportunities has been provided in the market overview section. In addition, the section comprises Porter’s five forces analysis to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global diabetic neuropathy market.

Global Diabetic Neuropathy Market: Segmentation

Based on disorder type, the diabetic neuropathy market is segmented as peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy. The disorder type market segments have been analyzed based on available approved treatment for disorders and patient data. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Based on treatment type, diabetic neuropathy market is segmented into drugs, radiotherapy and physiotherapy. The drug segment is further segmented into analgesic, antidepressant, anticonvulsant drugs and other drugs. The analgesic segment is further segmented into topical, opioid, NSAIDs. The antidepressant segment is segmented into TCAs, SNRIs, and SSRIs. Radiotherapy segment is segmented into Transcutaneous Electrical Nerve Stimulation (TENS), others.

The market segments have been extensively analyzed based on demand for available treatment, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Diabetic Neuropathy Market: Regional Analysis

Geographically, the global diabetic neuropathy market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, Russia, France, Spain, Italy, and Rest of Europe), Asia Pacific (Japan, India, China, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries and Rest of Middle East & Africa).

The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Global Diabetic Neuropathy Market: Competitive Analysis

The report also profiles major players in the global diabetic neuropathy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include – Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Pfizer, Inc., Lupin Limited, Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd, Arbor Pharmaceuticals, LLC, Depomed, Inc., and others.

The Global Diabetic Neuropathy Market is segmented as given below:

Global Diabetic Neuropathy Market, by Product

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

Global Diabetic Neuropathy Market, by Treatment Type

  • Drug
    • Analgesic
      • Topical
        • Capsaicin
        • Others
      • Opioids
        • Morphine
        • Others
      • NSAIDs
        • Ibuprofen
        • Naproxen
        • Others
    • Antidepressant
      • TCAs
        • Amitriptyline
        • Imipramine
        • Others
      • SNRIs
        • Duloxetine
        • Others
      • SSRIs
        • Citalopram
        • Paroxetin
        • Others
    • Anticonvulsants
      • Gabapentin
      • Pregabalin
      • Topimarate
      • Others
    • Other Drugs
  • Radiotherapy
    • TENS
    • Others
  • Physiotherapy

Global Diabetic Neuropathy Market, by Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacy
  • Online Pharmacy

Global Diabetic Neuropathy Market, by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • U.K.
    • Russia
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top